U.S. FDA Approves Humalog® 200 units/mL KwikPen®

Industry News

The U.S. FDA approved Humalog 200 units/mL KwikPen (insulin lispro 200 units/mL; U-200) indicated for improvement of glycemic control in both adults and children with type I and type II diabetes.  Humalog U-200 is a pre-filled pen containing fast-acting insulin that can be injected within 15 minutes before a meal or immediately after a meal.  This is a new concentrated formulation developed by global pharmaceutical company, Eli Lilly and Company and marks the first FDA approval of a concentrated mealtime insulin analog in the US.  This new formulation contains twice as many units of insulin as the U-100 formulation in the same volume and offers longer period between pen changes allowing for fewer changes every month for diabetic patients.


Original Article:


Subscribe to WXPress

Receive our newsletter and information on upcoming events.